Ajala, N
But consider what it means
If you are losing 0.5 to 1% of body weight per month and experiencing no side effects, the microdose is likely in your therapeutic window
Hence, while oral semaglutide and SGLT2 inhibitors offer comparable benefits for glycemic control and weight reduction, clinicians must consider the potential for skeletal muscle loss when prescribing SGLT2 inhibitors, particularly in those vulnerable to sarcopenia or frailty
Certain features warrant prompt medical evaluation: Severe muscle pain or weakness , particularly if accompanied by dark urine, which may indicate rhabdomyolysis (a rare but serious condition involving muscle breakdown) Joint swelling, redness, or warmth , which could suggest inflammatory arthritis or infection (septic arthritis) Pain that significantly impairs daily activities or does not respond to simple analgesia Systemic symptoms such as fever, unexplained weight loss (beyond expected therapeutic effect), or night sweats New or worsening pain following dose escalation, which may require dose adjustment or further investigation Sudden, severe pain in the right upper abdomen , possibly with fever or jaundice, which could indicate gallbladder disease (a recognised risk with GLP-1 receptor agonists) [1] [5] Patients should also seek advice if they experience other concerning adverse effects of Ozempic, including: Persistent nausea or vomiting leading to dehydration or reduced fluid intake Symptoms of hypoglycaemia (tremor, sweating, confusion), particularly if taking Ozempic with insulin or sulphonylureas Severe abdominal pain, which may indicate pancreatitis (a known but uncommon risk with GLP-1 receptor agonists) [1] [5] Visual changes or signs of diabetic retinopathy progression For urgent concerns outside of GP hours, patients should contact NHS 111
You can make finer dose adjustments (like stepping from 0.5 mg to 0.75 mg instead of jumping straight to 1.0 mg) and you can use split dosing strategies that pre-filled pens do not allow
